MP14-07 PERFORMANCE OF A NEW RISK ASSESSMENT TOOL FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA UNDERGOING CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA: REMARCC SCORE
M Mir, Carlotta Palumbo(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Eduard Roussel, Vital Hevia(Hospital Universitario Ramón y Cajal), J. Rubio‐Briones, Tobias Klatte(Helios Hospital Bad Saarow), Enrico Checcucci(University of Turin), Francesco Porpiglia(University of Turin), Selçuk Erdem(European Association of Urology), Estefanía Linares(Hospital Universitario La Paz), M. Albertsen(KU Leuven), Matthias Heck(TUM Klinikum), Umberto Capitanio(Vita-Salute San Raffaele University), Michele Marchioni(University of Chieti-Pescara), Riccardo Campi(University of Florence), Riccardo Autorino(Rush University Medical Center), Georgi Guruli(VCU Massey Comprehensive Cancer Center), Siska Van Bruwaene(AZ Groeninge), Alessandro Vecchia, Mireía Musquera(Surgical Specialties (Canada)), Alessandro Antonelli(University of Verona), Nicola Pavan(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Fadi Ghali(University of California San Diego), Francesco Claps(University of Trieste), Kriegmair Maximilian, Ithaar Derweesh(Rush University Medical Center), Andrea Minervini(University of Florence), Margaret Meagher(University of California San Diego), Mauricio D’Anna(Hospital Clínic de Barcelona)
Cited by 0
Related Papers
Urology practice during the COVID-19 pandemic
|Minerva Urologica e Nefrologica|2020|256
Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic?
|European Urology|2020|207
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
|Annals of Oncology|2009|205
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
|International Journal of Molecular Sciences|2022|190